Pharma Focus Asia

Ono Pharmaceutical Announces Collaboration Agreement with MOLCURE

Friday, March 24, 2023

Ono Pharmaceutical announced that it has entered into a drug discovery collaboration agreement with MOLCURE to discover and develop innovative antibody drugs for multiple targets utilizing MOLCURE’s AI-driven platform technology.

The new collaboration will accelerate biologics drug discovery efforts and bring innovative drugs for patients as soon as possible and will improve the prognosis and quality of life for patients around the world.

Under the terms of the agreement, MOCLURE will discover and identify antibodies or molecules for multiple targets of interest selected by Ono, using MOLCURE’s proprietary AI-driven platform technology. Ono will obtain option rights to exclusively and globally develop and commercialise therapeutic antibody drug candidates generated through the collaboration. Ono will pay to MOLCURE an upfront payment and research funding, and success-based milestone payments on research, development and commercialisation, as well as tiered royalties based on global net sales.

magazine-slider-imageCytiva - Supor Prime filtersMFA + MMA 2024CPHI China || PMEC China 2024Asia Healthcare Week 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference3rd World ADC Asia 2024LogiPharma Asia 2024